Phase I trial of nanoparticle albumin-bound paclitaxel in combination with gemcitabine in patients with thoracic malignancies

Journal of Thoracic Oncology

Volumn 3, Issue 5, 2008, Pages 521-526

  Stinchcombe, Thomas E ^a,c   Socinski, Mark A ^a   Lee, Carrie B ^a   Hayes, D Neil ^a   Moore, Dominic T ^b   Goldberg, Richard M ^a   Dees, E Claire ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b IL   (United States)

^c Chapel Hill NC 27599   (United States)

Author keywords

ABI 007; Abraxane; Esophageal cancer; Non small cell lung cancer; Small cell cancer; Taxane

Indexed keywords

ALBUMIN; GEMCITABINE; NANOPARTICLE; PACLITAXEL;

ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; ASTHENIA; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DEHYDRATION; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTROLYTE DISTURBANCE; ESOPHAGUS CANCER; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; HUMAN; KIDNEY FUNCTION; LIVER FUNCTION; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MALE; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUTROPENIA; NEUTROPHIL COUNT; PHASE 1 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PRURITUS; RASH; SENSORY NEUROPATHY; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

EID: 43049151113     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e31816de2a7     Document Type: Article

References (29)

1. J Crown M O'Leary The taxanes: an update Lancet 355 2000 1176 1178
2. WJ Gradishar S Tjulandin N Davidson Superior efficacy of albumin-bound paclitaxel, ABI-007, compared with polyethylated castor oil-based paclitaxel in women with metastatic breast cancer: results of a phase III Trial J Clin Oncol 23 2005 1 10
3. NA Rizvi GJ Riely CG Azzoli Phase I/II trial of weekly intravenous 130-nm albumin-bound paclitaxel as initial chemotherapy in patients with stage IV non-small-cell lung cancer J Clin Oncol 26 2008 639 643
4. JP Allerton CT Hagenstad RT Webb A phase II evaluation of the combination of paclitaxel protein-bound and carboplatin in the first line treatment of advanced non-small cell lung cancer (NSCLC) J Clin Oncol 24 18S 2006 abstract 7127. 2006 ASCO Annual Meetings Proceedings.
5. MJ Hawkins M Georgy A Makhson Dose escalation study of nab -paclitaxel followed by carboplatin a first line therapy in advanced non-small cell lung cancer (NSCLC) J Clin Oncol 24 18S 2006 abstract 7132. 2006 ASCO Annual Meetings Proceedings.
6. MR Green GM Manikhas S Orlov Abraxane, a novel Cremophor-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer Ann Oncol 17 2006 1263 1268
7. DG Pfister DH Johnson CG Azzoli American Society of Clinical Oncology Treatment of Unresectable Non-Small Cell Lung Cancer Guideline: Update 2003 J Clin Oncol 22 2004 330 353
8. J Treat CP Belani MJ Edelman A randomized phase III trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin in advanced (Stage IIIB, IV) non-small cell lung cancer (NSCLC): Update of the Alpha Oncology trial (A1-99002L) J Clin Oncol 23 16S 2005 abstract 7025; page 627s.
9. P Kosmidis N Mylonakis C Nicolaides Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small cell lung cancer: a phase III randomized trial J Clinical Oncol 20 2002 3578 3585
10. KS Albain S Nag G Calderillo-Ruiz Global phase III study of gemcitabine plus paclitaxel (GT) vs. paclitaxel (T) as frontline therapy for metastatic breast cancer (MBC): first report of overall survival J Clin Oncol 22 14S 2004 abstract 510.
11. P Therasse SG Arbuck EA Eisenhauer New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 2000 205 216
12. H Ozer JO Armitage CL Bennett 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel J Clin Oncol 18 2000 3558 3585
13. JD Rizzo AE Lichtin SH Woolf Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology J Clin Oncol 20 2002 4083 4107
14. NK Ibrahim N Desai S Legha Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel Clin Cancer Res 8 2002 1038 1044
15. NK Ibrahim B Samuels R Page Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer J Clin Oncol 23 2005 6019 6026
16. TE Stinchcombe MA Socinski CM Walko Phase I and pharmacokinetic trial of carboplatin and albumin-bound paclitaxel, ABI-007 (Abraxane®) on three treatment schedules in patients with solid tumors Cancer Chemother Pharmacol 60 2007 759 766
17. WJ Gradishar S Tjulandin N Davidson Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer J Clin Oncol 23 2005 7794 7803
18. MA Socinski MJ Schell A Peterman Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer J Clin Oncol 20 2002 1335 1343
19. LP James MG Kris RT Heelan A phase II study to determine if sensory neuropathy of nab-paclitaxel can be reduced by prolonging infusion in patients with non-small cell lung cancer (NSCLC J Clin Oncol 25 18S 2007 abstract 18087. 2007 ASCO Annual Meeting Proceedings Part I.
20. L Crino A Mosconi G Scagliotti G Selvaggi S Novello M Rinaldi Gemcitabine as second-line treatment for advanced non-small cell lung cancer: A phase II trial J Clin Oncol 17 1999 2081 2085
21. GA Masters L Declerck C Blanke Phase II trial of gemcitabine in refractory or relapsed small-cell lung cancer: Eastern Cooperative Oncology Group Trial 1597 J Clin Oncol 21 2003 1550 1555
22. AJ Wozniak K Belzer LK Heilbrun Mature results of a phase II trial of gemcitabine/paclitaxel given every 2 weeks in patients with advanced non-small-cell lung cancer Clin Lung Cancer 8 2007 313 318
23. H Gillenwater M Tynan S Natoli M Schell M Socinski Second-line gemcitabine in refractory stage IV non-small cell lung cancer: a phase II trial Clin Lung Cancer 2 2000 133 138
24. A Sandler R Gray MC Perry Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer N Engl J Med 355 2006 2542 2550
25. M Socinski S Novello JM Sanchez Efficacy and safety of sunitinib in previously treated, advanced non-small cell lung cancer: Preliminary Results of a multicenter phase II trial J Clin Oncol (Ann Meeting Proc) 24 18S 2006 7001
26. U Gatzemeier G Blumenschein F Fosella Phase II trial of single-agent sorafenib in patients with advanced non-small cell lung carcinoma J Clin Oncol (Annual Meeting Proc) 24 18S 2006 7002
27. JR Kroep G Giaccone DA Voorn Gemcitabine and paclitaxel: pharmacokinetic and pharmacodynamic interactions in patients with non-small-cell lung cancer J Clin Oncol 17 1999 2190 2197
28. S Fogli R Danesi F De Braud Drug distribution and pharmacokinetic/pharmacodynamic relationship of paclitaxel and gemcitabine in patients with non-small-cell lung cancer Ann Oncol 12 11 2001 1553 1559
29. T De Pas F de Braud R Danesi Phase I and pharmacologic study of weekly gemcitabine and paclitaxel in chemo-naive patients with advanced non-small-cell lung cancer Ann Oncol 11 7 2000 821 827